Compound News and Research

RSS

SMER28 can reduce beta-amyloid accumulation in patients with Alzheimer's disease

If you can't stop the beta-amyloid protein plaques from forming in Alzheimer's disease patients, then maybe you can help the body rid itself of them instead. At least that's what scientists from New York were hoping for when they found a drug candidate to do just that.

8 Mar 2011

Ambry, RainDance enter new collaboration to develop and commercialize ADME screening

RainDance Technologies, Inc. and Ambry Genetics, today announced a new collaboration focused on the development and commercialization of a comprehensive drug absorption, distribution, metabolism, and excretion genetic screening panel for use on next-generation sequencing systems.

8 Mar 2011

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

7 Mar 2011

CPCHE launches multi-year project to promote healthier home energy retrofits

Home energy retrofits tackle climate change and when done right they should make homes healthier, while aiding families struggling with utility bills.

6 Mar 2011

FDA accepts Lundbeck's clobazam NDA for review

Lundbeck Inc. today announced the U.S. Food and Drug Administration has accepted for review a New Drug Application for the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome in patients two years and older.

5 Mar 2011

Alcohol, marijuana and methamphetamines are common abuse substances

A new study shows that the most commonly abused substances among those 18 and older referred to substance abuse treatment from parole or probation was alcohol, followed by marijuana and methamphetamines.

4 Mar 2011

Scientist develops cryo-electron microscopy to clarify salmonellae structure

Bacteria like salmonellae infect their host cells by needle-shaped extensions which they create in large numbers during an attack. A group of Vienna-based scientists headed by Thomas Marlovits employed recently developed methods of cryo-electron microscopy and have been able to clarify the structure of this infection apparatus on the near-atomic scale.

4 Mar 2011

Triptolide isolated from Chinese medicinal plant blocks gene control machinery in cells

Researchers at the Johns Hopkins School of Medicine have discovered that a natural product isolated from a traditional Chinese medicinal plant commonly known as thunder god vine, or lei gong teng, and used for hundreds of years to treat many conditions including rheumatoid arthritis works by blocking gene control machinery in the cell. The report, published as a cover story of the March issue of Nature Chemical Biology, suggests that the natural product could be a starting point for developing new anticancer drugs.

4 Mar 2011

Lactate plays critical role in formation of long-term memory

Researchers from Mount Sinai School of Medicine have found that lactate, a type of energy fuel in the brain, plays a critical role in the formation of long-term memory. These findings have important implications for common illnesses like Alzheimer's disease, other neurodegenerative disorders, aging-related memory impairment and diabetes. The research is published in the March 4th issue of the journal Cell.

4 Mar 2011

Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment

Palatin Technologies, Inc. today announced that the U.S. Food and Drug Administration has cleared Palatin's request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development for treatment of acute exacerbations of asthma.

4 Mar 2011

Honey for wound healing: Study

Researchers from the University of Queensland (UQ) and the Queensland Government have found honey from an Australian native myrtle to be effective as an anti-bacterial agent that can be used to treat wounds and viruses.

3 Mar 2011

DNA methylation patterns can accurately detect early bowel cancer

Cancer Research UK scientists have discovered for the first time that DNA methylation patterns - a key process in cell development - could accurately detect early bowel cancer, according to research published in Gut, today.

3 Mar 2011

Lixte receives $244,479.25 U.S. government grant for QTDP program

Lixte Biotechnology Holdings announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project.

3 Mar 2011

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

Omeros Corporation today announced that it has identified compounds that interact selectively with two orphan G protein-coupled receptors linked to pancreatic cancer and cognitive disorders.

3 Mar 2011

ITI, Takeda collaborate to develop and commercialize PDE1 inhibitors for schizophrenia

Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

3 Mar 2011

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.

2 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

New study: Enzyme that metabolizes vitamin D can predict lung cancer survival

Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.

1 Mar 2011

Heterotaxin useful for studying intestinal birth defects may also inhibit cancerous tumor growth

In an interesting bit of scientific serendipity, researchers at North Carolina State University have found that a chemical compound useful for studying the origins of intestinal birth defects may also inhibit the growth and spread of cancerous tumors.

1 Mar 2011

Compound News and Research

SMER28 can reduce beta-amyloid accumulation in patients with Alzheimer's disease

Ambry, RainDance enter new collaboration to develop and commercialize ADME screening

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

CPCHE launches multi-year project to promote healthier home energy retrofits

FDA accepts Lundbeck's clobazam NDA for review

Alcohol, marijuana and methamphetamines are common abuse substances

Scientist develops cryo-electron microscopy to clarify salmonellae structure

Triptolide isolated from Chinese medicinal plant blocks gene control machinery in cells

Lactate plays critical role in formation of long-term memory

Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment

Honey for wound healing: Study

DNA methylation patterns can accurately detect early bowel cancer

Lixte receives $244,479.25 U.S. government grant for QTDP program

Omeros identifies orphan GPCR compounds associated to pancreatic cancer, cognitive disorders

ITI, Takeda collaborate to develop and commercialize PDE1 inhibitors for schizophrenia

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

New study: Enzyme that metabolizes vitamin D can predict lung cancer survival

Heterotaxin useful for studying intestinal birth defects may also inhibit cancerous tumor growth

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News